Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat for HFrEF with pulmonary hypertension
jRCT1051230206Suspended
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vericiguat in heart failure with reduced ejection fraction (HFrEF) and pulmonary hypertension (PH). Primary endpoint: Change in pulmonary vascular resistance. Started Jun 2025; status: suspended.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)pulmonary hypertension (PH)
Beyond the preview
Go deeper on jRCT1051230206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051230206.